FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and is an antibody capable of specifically binding to the Axl protein and also to be internalised after binding. Invention also relates to a conjugate comprising such an antibody. Invention also covers use of said antibody and conjugate for the treatment of cancer.
EFFECT: invention widens the range of agents for treating cancer, characterised by overexpression of the Axl protein.
24 cl, 15 dwg, 12 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIGEN-BINDING PROTEIN AND ITS APPLICATION AS A PRODUCT FOR ADDRESS DELIVERY IN TREATMENT OF CANCER | 2012 |
|
RU2650771C1 |
| ANTI-IGF-1R ANTIBODY AND USE THEREOF AS AN ADDRESS VECTOR FOR CANCER TREATMENT | 2015 |
|
RU2698977C2 |
| ANTIBODY TO CLDN18.2 AND ITS USE | 2018 |
|
RU2797709C2 |
| CD37 BINDING MOLECULES AND IMMUNOCONJUGATES | 2011 |
|
RU2610662C9 |
| ANTIBODIES TO FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND APPLICATION | 2011 |
|
RU2610663C2 |
| ANTIBODY AND MEDICINAL AGENT CONJUGATE AND USE THEREOF FOR TREATING CANCER | 2015 |
|
RU2685259C2 |
| BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE | 2012 |
|
RU2605390C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| MODIFIED EXOTOXIN A PSEUDOMONADES | 2014 |
|
RU2687143C2 |
| ALLOSTERIC ANTIBODIES AGAINST HUMAN HER3 NON COMPETITIVE FOR NEUREGULIN AND USE THEREOF | 2013 |
|
RU2704228C2 |
